Wang Qiuxia, Sun Zhihao, Li Jingzhi, Qin Tao, Ma Hongwei, Chen Sujuan, Peng Daxin, Liu Xiufan
College of Veterinary Medicine, Yangzhou University, 48 East Wenhui Road, Yangzhou, Jiangsu, 225009, People's Republic of China.
Jiangsu Co-Innovation Center for the Prevention and Control of Important Animal Infectious Disease and Zoonoses, Yangzhou, 225009, Jiangsu, People's Republic of China.
BMC Vet Res. 2021 Jan 7;17(1):22. doi: 10.1186/s12917-020-02725-5.
Hemagglutinin is a major surface protein in influenza A virus (IAV), and HA2 is relative conserved among different IAVs. It will be meaningful to identify broad-spectrum epitopes based on the HA2 protein.
Overlapping peptides of the HA2 protein of the H5N1 IAV A/Mallard/Huadong/S/2005 were synthesized and loaded on modified silica gel film to form a microarray, and antisera against different subtypes of IAVs were used to screen universal epitopes. The selected epitope was further confirmed by western blotting using anti-peptide immune serum and viruses rescued with amino acid substitution. The results showed that 485-FYHKCDNECME-495 of the H5 14th peptide in HA2 had broad-spectrum binding activity with antisera against H1, H3, H4, H5, H6, H7, H8, H9, and H10 subtype IAV. Substitution of amino acids (K or D) in rescued viruses resulted in decreased serum binding, indicating that they were critical residues for serum binding activity. In Immune Epitope Database, some epitopes containing 14-4 peptide were confirmed as MHC-II-restricted CD4 T cell epitope and had effects on releasing IL-2 or IFN.
The identified epitope should be a novel universal target for detection and vaccine design and its ability to generate immune protection needs further exploration.
血凝素是甲型流感病毒(IAV)的主要表面蛋白,且HA2在不同IAV中相对保守。基于HA2蛋白鉴定广谱表位具有重要意义。
合成了H5N1 IAV A/野鸭/华东/S/2005的HA2蛋白重叠肽,并将其负载于修饰硅胶膜上形成微阵列,使用针对不同IAV亚型的抗血清筛选通用表位。通过使用抗肽免疫血清和氨基酸替代拯救的病毒进行蛋白质印迹进一步确认所选表位。结果显示,HA2中H5第14肽的485-FYHKCDNECME-495与针对H1、H3、H4、H5、H6、H7、H8、H9和H10亚型IAV的抗血清具有广谱结合活性。拯救病毒中氨基酸(K或D)的替代导致血清结合减少,表明它们是血清结合活性的关键残基。在免疫表位数据库中,一些包含14-4肽的表位被确认为MHC-II限制性CD4 T细胞表位,并对释放IL-2或IFN有影响。
鉴定出的表位应是检测和疫苗设计的新型通用靶点,其产生免疫保护的能力有待进一步探索。